SAN DIEGO, CA, Gallant Therapeutics, an animal health biotechnology company has raised a Series A financing, securing over $15 million.
Gallant Therapeutics, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful completion of its Series A financing, securing over $15 million. The financing round was led by BOLD Capital and joined by new investors Digitalis Ventures and Hill Creek Partners.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
